Legacy Programs

ADU-S100

Lead Candidate from the STING Pathway Activator Technology

ADU-S100 is a novel synthetic molecule cyclic dinucleotide that activates human STING (STimulator of INterferon Genes) and is being developed in collaboration with Novartis. ADU-S100 is being evaluated in a Phase 2 clinical trial in adults with PD-L1 positive recurrent or metastatic head and neck cancer. The trial is evaluating the efficacy and safety of intratumoral ADU-S100 (also referred to as MIW815) administered with pembrolizumab in the first-line setting. If you are interested in this study and to find out more, please visit ClinicalTrials.gov (NCT03937141) for your nearest site contact and location information.

cGAS-STING Inhibitors

The cGAS-STING Pathway Inhibitor program is based on the premise that inhibition of the STING pathway will lead to a reduction in the immune response associated with certain autoimmune diseases. In collaboration with Eli Lilly and Company, the cGAS-STING Pathway Inhibitor program is exploring the development of novel small molecule immunotherapies for autoimmune and other inflammatory diseases.

LEGACY PIPELINE

Phase Indication Trial Number Trial Name

ADU-S100 / MIW815 (STING Pathway Activator)

Phase 1 Multiple tumors NCT02675439 A Phase I, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection Alone or in Combination With Ipilimumab to Patients With Advanced/Metastatic Solid Tumors or Lymphomas
Phase 1 Multiple tumors NCT03172936 A Phase I, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection in Combination with PDR001, an investigational anti-PD-1 checkpoint inhibitor, to Patients With Advanced/Metastatic Solid Tumors or Lymphomas
Phase 2 Head & Neck Cancer NCT03937141 A Phase 2, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of ADU-S100 (MIW815) Administered Intratumorally in Combination with Pembrolizumab in a First-line Setting to Adults with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

pLADD Immunotherapy​

Phase 1 Colorectal Cancer NCT03189030 A Phase 1 Safety and Tolerability Study of Personalized Live, Attenuated, Double-Deleted Listeria Monocytogenes (pLADD) Immunotherapy in Adults With Metastatic Colorectal Cancer

cGAS-STING Pathway Inhibitors

Discovery Autoimmune and Inflammatory diseases